ECEESPE2025 ePoster Presentations Diabetes and Insulin (245 abstracts)
Use of automated insulin delivery systems in pregnant women with type 1 diabetes: real-world data
Lara Albert Fàbregas 1 , Alba Hernández Lázaro 1 , Valeria Arsentales Montalva 1 , Ismael Capel Flores 1 , David Subías Andújar 1 , Laia Casamitjana Espuña 1 , María Florencia Luchtenberg 1 & Mercedes Rigla Cros 1
1Endocrinology and Nutrition Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain
JOINT3224
Introduction: The use of commercially available automated insulin delivery (AID) systems during pregnancy remains controversial. In this retrospective study, we evaluated the glycemic and pregnancy outcomes, and AID parameters of 13 women who received AID therapy (9 Minimed 780G and 4 Control-IQ) at our hospital between 2021 and 2024. We obtained CGM and insulin pump data from online platforms and assessed diabetes complications, maternal, and fetal outcomes using the medical records.
Results: The median age was 34 years (IQR: 31–39), with a median diabetes duration of 22 years (IQR: 16-29) and a median BMI of 23 kg/m2 (IQR: 22-32). 62% of the pregnancies were planned. TIR >70% was achieved in 9/12 (1st trimester), 9/13 (2nd trimester), and 7/13 (3rd trimester) pregnancies. Insulin dose, daily carbs and number of meals increased throughout pregnancy whereas the carbohydrate-to-insulin ratio gradually declined (Table 1). At delivery, gestational age was 37.3 weeks (37–38). 7/13 women had a cesarean section and 2/13 had mild pre-eclampsia. 7/13 newborns were large for gestational age and 4/13 were admitted to the neonatal intensive care unit (one spontaneous preterm birth and one spontaneous hemoperitoneum).
| Initial (First visit) | First Trimester (4-15 weeks’ gestation) | Second Trimester (16-27 weeks’ gestation) | Third Trimester (28-delivery)HbA1c (%) | |
| HbA1c (%) | 6.3 (6.3-6.6) | 6.3 (6.2-6.5) | 5.9 (5.8-6.1) | 6.0 (5.9-6.3) |
| glucose management indicator (%) | 6.6 (6.5-6.8) | 6.4 (6.3-6.7) | 6.4 (6.3-6.5) | 6.3 (6.2-6.4) |
| Mean sensor glucose (mg/dL) | 136 (126-144) | 129 (126-139) | 128 (125-134) | 125 (123-130) |
| Coefficient of Variation (%) | 29 (28-32) | 31 (29-33) | 30 (29-31) | 28 (27-30) |
| 63-140 mg/dL (%) | 60 (56-66) | 66 (58-70) | 67 (59-71) | 70 (65-77) |
| > 140 mg/dL (%) | 39 (33-44) | 33 (29-41) | 32 (27-38) | 29 (23-35) |
| < 63 mg/dL (%) | 0.2 (0-1) | 1 (1-2) | 2 (1-2) | 1 (1-2) |
| Total daily insulin dose (UI) | 40 (32-46) | 41 (30-52) | 45(34-63) | 59(44-72) |
| Total insulin per body weight (UI/kg) | 0.56 (0.50-0.69) | 0.61 (0.53-0.68) | 0.58 (0.52-0.79) | 0.71 (0.61-0.80) |
| Daily Carbs (g) | 133(116-159) | 160 (130-171) | 175(148-186) | 175 (162-181) |
| Number of meals/day | 4.7 (4.3-5.2) | 5.3 (4.7-6.2) | 6.1 (4.6-7) | 6.4 (4.8-6.5) |
| ICR breakfast (g/UI) | 6.6 (4.2-7.9) | 6.2 (4-7.7) | 4.8 (3.2-6.8) | 4.4 (3.3-5.9) |
| ICR lunch (g/UI) | 6.2 (5.2-7.9) | 6.4 (4.8-7.5) | 5.6 (4.6-7.4) | 4.8 (4.1-6.6) |
| ICR dinner (g/UI) | 6.6 (5.2-9.2) | 7.6 (4.9-8.7) | 6.4 (5.0-7.1) | 5.2 (4.2-6.2) |
| Data are presented as median (IQR); ICR, insulin-to-carbohydrate ratio | ||||
Conclusion: AID systems help maintain glycemic control during pregnancy without increasing the rates of hypoglycemia.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more